Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Bernard Ponsard"'
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 7, Iss 1, Pp 1-16 (2022)
Abstract Background Radionuclide therapy (RNT) has become a very important treatment modality for cancer nowadays. Comparing with other cancer treatment options, sufficient efficacy could be achieved in RNT with lower toxicity. β− emitters are fre
Externí odkaz:
https://doaj.org/article/a35df7f7f72446fcaa7826a9946c38c7
Autor:
Michiel Van de Voorde, Charlotte Duchemin, Reinhard Heinke, Laura Lambert, Eric Chevallay, Thomas Schneider, Miranda Van Stenis, Thomas Elias Cocolios, Thomas Cardinaels, Bernard Ponsard, Maarten Ooms, Thierry Stora, Andrew R. Burgoyne
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Samarium-153 (153Sm) is a highly interesting radionuclide within the field of targeted radionuclide therapy because of its favorable decay characteristics. 153Sm has a half-life of 1.93 d and decays into a stable daughter nuclide (153Eu) whereupon β
Externí odkaz:
https://doaj.org/article/4a450b7f4e2d4e3d8dce6029aafc6dd3
Autor:
Katharina A. Domnanich, Cristina Müller, Martina Benešová, Rugard Dressler, Stephanie Haller, Ulli Köster, Bernard Ponsard, Roger Schibli, Andreas Türler, Nicholas P. van der Meulen
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 2, Iss 1, Pp 1-17 (2017)
Abstract Background Radiotheragnostics makes use of the same molecular targeting vectors, labeled either with a diagnostic or therapeutic radionuclide, ideally of the same chemical element. The matched pair of scandium radionuclides, 44Sc and 47Sc, s
Externí odkaz:
https://doaj.org/article/7fc61dd465b94196b6803e49015663cc
Autor:
Katharina A. Domnanich, Cristina Müller, Renata Farkas, Raffaella M. Schmid, Bernard Ponsard, Roger Schibli, Andreas Türler, Nicholas P. van der Meulen
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 1, Iss 1, Pp 1-19 (2016)
Abstract Background Recently, 44Sc (T1/2 = 3.97 h, Eβ+ av = 632 keV, I = 94.3 %) has emerged as an attractive radiometal candidate for PET imaging using DOTA-functionalized biomolecules. The aim of this study was to investigate the potential of usin
Externí odkaz:
https://doaj.org/article/426a2a03dc4a46d2ad31181509126f76
Autor:
Klaudia Siwowska, Patrycja Guzik, Katharina A. Domnanich, Josep M. Monné Rodríguez, Peter Bernhardt, Bernard Ponsard, Roger Hasler, Francesca Borgna, Roger Schibli, Ulli Köster, Nicholas P. van der Meulen, Cristina Müller
Publikováno v:
Pharmaceutics, Vol 11, Iss 8, p 424 (2019)
Targeted radionuclide therapy with 177Lu- and 90Y-labeled radioconjugates is a clinically-established treatment modality for metastasized cancer. 47Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy β
Externí odkaz:
https://doaj.org/article/be741ebad0834376aa28dddcac95c738
Autor:
Clemens Decristoforo, Sason Feldkamp Hayashi, Cecile Bordeau, Ferid Haddad, David Viertl, Claire Deville, Clive Naidoo, Kristina Søborg Pedersen, Mikael Jensen, Ulli Köster, João Galamba Correia, Lurdes Gano, Frank Bruchertseifer, Kristof Baete, Renata Mikolajczak, Sean Collins, Susanne Geistlich, Nick van der Meulen, Bernard Ponsard, Michiel Van de Voorde, Monica Campillos
Radiopharmaceuticals are considered Medicinal Products, thereby they must be prepared and applied within the regulated area of pharmaceuticals. This includes radionuclides, which have seen extraordinary advancements in research and development over t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f96759344bd6e15f10c0da8cf03445a
Autor:
Diana Melis, Tomas Opsomer, Bernard Ponsard, Andrew Burgoyne, Gilles Gasser, Michiel Van de Voorde, Maarten Ooms
Publikováno v:
Nuclear Medicine and Biology. :S38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1a436d6407ca7e29aa86807d98aaa21
https://doi.org/10.1016/s0969-8051(22)02165-5
https://doi.org/10.1016/s0969-8051(22)02165-5
Autor:
Koen Vermeulen, Michiel Van de Voorde, Noami Daems, Charlotte Duchemin, Sunay Rodriguez, Melissa Crabbé, Reinhard Heinke, Bernard Ponsard, Lorain Geenen, Julie Nonnekens, Laura Lambert, Charlotte Segers, Cyril Bernerd, Andrew Burgoyne, Thomas Cocolios, Thierry Stora, Maarten Ooms
Publikováno v:
Nuclear Medicine and Biology. :S57
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be6e6c13929822facc3d0739af699e1e
https://doi.org/10.1016/s0969-8051(22)02206-5
https://doi.org/10.1016/s0969-8051(22)02206-5
Autor:
Koen Vermeulen, Michiel Van de Voorde, Noami Daems, Charlotte Duchemin, Sunay Rodriguez, Melissa Crabbé, Reinhard Heinke, Bernard Ponsard, Lorain Geenen, Julie Nonnekens, Laura Lambert, Cyril Bernerd, Andrew Burgoyne, Thomas Cocolios, Thierry Stora, Maarten Ooms
Publikováno v:
Nuclear Medicine and Biology. :S20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58aaea3ffaa41c6756bbe3005a2bf754
https://doi.org/10.1016/s0969-8051(22)00085-3
https://doi.org/10.1016/s0969-8051(22)00085-3
Autor:
Francesca Borgna, Bernard Ponsard, Patrycja Guzik, Cristina Müller, Roger Schibli, Nicholas P. van der Meulen, Klaudia Siwowska, Roger Hasler, Katharina Anna Domnanich, Josep M Monné Rodríguez, Ulli Köster, Peter Bernhardt
Publikováno v:
'Pharmaceutics ', vol: 11, pages: 424-1-424-13 (2019)
Pharmaceutics
Volume 11
Issue 8
Pharmaceutics, Vol 11, Iss 8, p 424 (2019)
Pharmaceutics, 11 (8)
Pharmaceutics
Volume 11
Issue 8
Pharmaceutics, Vol 11, Iss 8, p 424 (2019)
Pharmaceutics, 11 (8)
Targeted radionuclide therapy with 177Lu- and 90Y-labeled radioconjugates is a clinically-established treatment modality for metastasized cancer. 47Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy &be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44fcb732f017b39bbc8649d2ed9a36d8
https://doi.org/10.5167/uzh-175813
https://doi.org/10.5167/uzh-175813